Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.4628
Abstract: 4628Background: ESPAC-4 study showed that GemCap conferred a survival benefit over gemcitabine monotherapy in resected PC patients. ESPAC-4 included patients with median age of 65 years (37-81) and...
read more here.
Keywords:
gemcap;
efficacy biweekly;
gemcitabine;
safety efficacy ... See more keywords